CJC-1295 No DAC / Ipamorelin 10mg

It is a co-lyophilized research blend containing 5mg of CJC-1295 No DAC and 5mg of ipamorelin per vial. It is supplied strictly for in-vitro and laboratory research.

“No DAC” is marketplace nomenclature used for a short-acting modified GRF(1-29)-type peptide without the albumin-binding Drug Affinity Complex used in long-acting CJC-1295 research. The two should not be treated as chemically or pharmacokinetically identical.

Ipamorelin is a pentapeptide growth-hormone secretagogue studied at the GHS receptor. Published work includes receptor-selectivity studies and pharmacokinetic/pharmacodynamic research in healthy volunteers.

No clinical claim is made for this commercial formulation. The selected literature describes the individual pathways, ipamorelin, or other GHRH/GHS research systems and should not be read as proof of a combined clinical effect.

The long-acting CJC-1295 paper documents the DAC-bearing analog and helps clarify the naming distinction. It is not evidence that the No-DAC component has the same structure, half-life or pharmacology.

Every batch goes through three layers of quality control. Our manufacturer runs its own QC and has its production independently tested by Janoshik Analytical. Then Vanguard or Janoshik tests every batch we stock again, for identity, HPLC purity, net content and endotoxins before we approve it for sale.

Every approved batch has its lab report on the Test Results page.

The product contains two chemically distinct peptides. A single molecular weight, formula or CAS number would misrepresent the blend as one compound.

Keep the sealed lyophilized vial at −20°C, protected from light, and avoid repeated freeze-thaw cycles. Follow the label and batch documentation. Prime Peptides release testing does not independently establish shelf life.